AstraZeneca tests the "subgroups cannot save a failed trial" rule
A prespecified 62% survival benefit in a kappa-isotype cohort of a failed Phase 3 is now AstraZeneca's filing strategy — and a live audit of how much subgroup evidence the agencies will actually accept.